Avidity Partners Management
Avidity Partners Management reported 45 stocks worth $624M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are DNTH (32.9%), CGON (15.9%) and ORKA (11.6%). Compared with Q1 2026, the fund opened new positions in MOBI, IMUX and SENS, added to CGON, TEM and GPCR, trimmed DNTH, ORKA and JBIO and sold out of IMUX, HUM and SCYX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  DNTH Dianthus Therapeutics Inc | $205M | 32.9% | 2.1M | −2.1M (−50%) | 8 of 8 | |
| 2 |  CGON CG Oncology Inc | $99.4M | 15.9% | 1.4M | +110K (+9%) | 8 of 8 | |
| 3 |  ORKA Oruka Therapeutics Inc | $72.4M | 11.6% | 760K | −760K (−50%) | 8 of 8 | |
| 4 |  JBIO Jade Biosciences Inc | $37.8M | 6.0% | 1.7M | −1.1M (−39%) | 5 of 8 | |
| 5 |  ELVN Enliven Therapeutics Inc | $27.9M | 4.5% | 550K | −250K (−31%) | 6 of 8 | |
| 6 |  CATX Perspective Therapeutics Inc | $21.5M | 3.4% | 6.3M | −5.8M (−48%) | 8 of 8 | |
| 7 |  AKTS Aktis Oncology Inc | $15.6M | 2.5% | 484K | −453K (−48%) | 2 of 8 | |
| 8 |  PVLA Palvella Therapeutics Inc NE | $10.7M | 1.7% | 70K | −70K (−50%) | 3 of 8 | |
| 9 |  MOBI Mobia Med Inc | $10.7M | 1.7% | 798K | New position | 1 of 8 | |
| 10 |  RGEN Repligen Corp | $10.6M | 1.7% | 78K | −78K (−50%) | 5 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 IMUX Immunic Inc | $13.9M | 7.4M |
 HUM Humana Inc | $5.9M | 25K |
 SCYX Scynexis Inc | $3.8M | 4.2M |
 ICLR Icon PLC | $3.7M | 32K |
 NTRA Natera Inc | $3.7M | 18K |
🔒 Free account: see all 16.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Avidity Partners Management 13F FAQ
What does Avidity Partners Management own?
Avidity Partners Management reported 45 stocks worth $624M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are DNTH (32.9%), CGON (15.9%) and ORKA (11.6%). The table above lists every position in the filing (the top 10 without an account).
What did Avidity Partners Management buy and sell in Q2 2026?
Compared with Q1 2026: 9 new positions, 4 added to, 27 trimmed and 16 sold out. New positions include MOBI, IMUX and SENS. It sold all of IMUX, HUM and SCYX.
When will Avidity Partners Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Avidity Partners Management's portfolio worth?
The Q2 2026 filing reports $624M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.